• Suzhou

      Suzhou Manufacturing Center: Technology scale up and transfer, and the commercial facility. The company has selected Suzhou as a strategically superior location to meet the need of the clinical samples manufacturing, because of its local biotech landscape, lower business cost and government benefits, as well as it is part of the Yangtze River Delta Integrated Development set up.

    • Shanghai

      Immune & Cell Therapy research activities with the powerful resources including but not limited to the talents, information and data, capital and biotech ecology from Zhangjiang Tech Park and the larger Shanghai area.

    • Suzhou

      Suzhou Manufacturing Center: Technology scale up and transfer, and the commercial facility. The company has selected Suzhou as a strategically superior location to meet the need of the clinical samples manufacturing, because of its local biotech landscape, lower business cost and government benefits, as well as it is part of the Yangtze River Delta Integrated Development set up.

    • Shanghai

      Immune & Cell Therapy research activities with the powerful resources including but not limited to the talents, information and data, capital and biotech ecology from Zhangjiang Tech Park and the larger Shanghai area.

    Milestones
    • 09/2020

      Immunofoco Operation Started at Shanghai Zhangjiang Pharma Valley

      09/2020
      1/12
    • 12/2020

      Completed Angel Round Financing

      12/2020
      2/12
    • 05/2021

      IMC001 project started Investigator-Initiated Trials

      Funded by Science and Technology Commission of Shanghai

      05/2021
      3/12
    • 07/2021

      Awarded as "Science and Technology Leading Talent" of Suzhou Industrial Park

      07/2021
      4/12
    • 10/2021

      Completed Series A Financing of RMB100 Million

      Shanghai Galileo R&D Center Officially Opened

      10/2021
      5/12
    • 07/2022

      IMC002 was Granted Orphan Drug Designation by FDA

      07/2022
      6/12
    • 08/2022

      Suzhou Pilot Manufacturing Center Officially Opened

      08/2022
      7/12
    • 09/2022

      Oral Presentation of the Progress of IMC001 IIT Study at ESMO2022

      09/2022
      8/12
    • 12/2022

      Completed Series A+ Financing of Nearly RMB 200 Million

      Awarded as "Suzhou Innovation and Entrepreneurship Leading Talent"

      12/2022
      9/12
    • 01/2023

      IMC002 IND Application was Accepted by CDE

      01/2023
      10/12
    • 03/2023

      IMC002 IND application received the US FDA approval.

      03/2023
      11/12
    • 04/2023

      IMC002 IND application received approval from China CDE

      04/2023
      12/12
    • 09/2020

      Immunofoco Operation Started at Shanghai Zhangjiang Pharma Valley

    • 12/2020

      Completed Angel Round Financing

    • 05/2021

      IMC001 project started Investigator-Initiated Trials

      Funded by Science and Technology Commission of Shanghai

    • 07/2021

      Awarded as "Science and Technology Leading Talent" of Suzhou Industrial Park

    • 10/2021

      Completed Series A Financing of RMB100 Million

      Shanghai Galileo R&D Center Officially Opened

    • 07/2022

      IMC002 was Granted Orphan Drug Designation by FDA

    • 08/2022

      Suzhou Pilot Manufacturing Center Officially Opened

    • 09/2022

      Oral Presentation of the Progress of IMC001 IIT Study at ESMO2022

    • 12/2022

      Completed Series A+ Financing of Nearly RMB 200 Million

      Awarded as "Suzhou Innovation and Entrepreneurship Leading Talent"

    • 01/2023

      IMC002 IND Application was Accepted by CDE

    • 03/2023

      IMC002 IND application received the US FDA approval.

    • 04/2023

      IMC002 IND application received approval from China CDE